Bioresorbable foaming tissue dressing
View Patent ↗Provided is a flowable bioresorbable tissue dressing comprising a gas-forming porogen and a gel or gel-forming solution. Also provided is kits for preparing the above-described tissue dressing. Further provided are methods of treating a tissue site of a mammal with the above dressing. Also provided is a reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site.
1. A dressing for applying reduced-pressure treatment to a tissue site, comprising:
a gas-forming porogen comprising a particle size for developing sufficient porosity for conducting reduced pressure;
a bioresorbable microsphere; and
a bioresorbable gel or a bioresorbable gel-forming solution in a mixture with the gas-forming porogen and the bioresorbable microsphere;
wherein the mixture is flowable, and after delivery to the tissue site, forms a scaffold comprising pores of at least 50 micrometers in diameter for delivering reduced pressure through the scaffold; and
wherein the dressing is bioresorbable.
2. The dressing of claim 1 , wherein the porogen is a mixture of an acid and a carbonate salt.
3. The dressing of claim 2 , wherein the acid is citric acid.
4. The dressing of claim 2 , wherein the carbonate salt is ammonium bicarbonate, sodium bicarbonate or calcium carbonate.
5. The dressing of claim 1 , wherein the gel or gel-forming solution comprises collagen, gelatin, hyaluronic acid, or combinations thereof.
6. The dressing of claim 1 , further comprising a non-gas forming porogen.
7. The dressing of claim 6 , wherein the non-gas forming porogen is a salt.
8. The dressing of claim 7 , wherein the salt is sodium chloride or potassium chloride.
9. The dressing of claim 6 , wherein the non-gas forming porogen is a sugar.
10. The dressing of claim 1 , wherein the bioresorbable microsphere comprises polylactide (PLA), polyglycolic acid (PLG), poly(lactide-co-glycolide) (PLGA), polyethylene glycol-PLA, PLA-polycaprolactone (PCL), a polyorthoester, a polyphosphazene, or a polyphosphoester.
11. The dressing of claim 1 , further comprising a compound that adds stiffness to the dressing.
12. The dressing of claim 11 , wherein the compound is calcium sulfate hemihydrate.
13. The dressing of claim 1 , further comprising a bioactive agent.
14. The dressing of claim 13 , wherein the bioactive agent is an antibiotic.
15. The dressing of claim 13 , wherein the bioactive agent is a growth factor.
16. The dressing of claim 15 , wherein the growth factor is growth hormone (GH), a bone morphogenetic protein (BMP), transforming growth factor-α(TGF-α), a TGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GMCSF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumor necrosis factor-α(TNF-α), or nerve growth factor (NGF).
17. The dressing of claim 1 , further comprising a mammalian cell.
18. The dressing of claim 17 , wherein the mammalian cell is an embryonic stem cell, an adult stem cell, an induced pluripotent stem cell, an epithelial cell, an endothelial cell, a mesenchymal cell, a muscle cell, a fibroblast, a chondrocyte, an adipocyte, or an osteocyte.
19. The dressing of claim 17 , wherein the mammalian cell is a human cell.
20. The dressing of claim 1 , wherein the pores of the scaffold are between approximately 50 micrometers and 1,500 micrometers in diameter.
21. The dressing of claim 1 , wherein the pores of the scaffold are between approximately 100 micrometers and 500 micrometers in diameter.
22. A tissue dressing for applying reduced-pressure treatment to a tissue site, comprising:
a gas-forming porogen comprising a particle size for developing sufficient porosity for conducting reduced pressure;
a bioresorbable microsphere; and
a gel or gel-forming solution in a mixture with the gas-forming porogen and the bioresorbable microsphere;
wherein the mixture is flowable, and after delivery to the tissue site, forms a scaffold comprising pores of at least 50 micrometers in diameter for delivering reduced pressure through the scaffold.
23. The dressing of claim 22 , wherein the porogen is a mixture of an acid and a carbonate salt.
24. The dressing of claim 23 , wherein the acid is citric acid.
25. The dressing of claim 23 , wherein the carbonate salt is ammonium bicarbonate, sodium bicarbonate or calcium carbonate.
26. The dressing of claim 22 , wherein the gel or gel-forming solution comprises a polyacrylate, a poloxamer, a polyethylene glycol, chitosan, collagen, gelatin, hyaluronic acid, or combinations thereof.
27. The dressing of claim 22 , wherein the gel or gel-forming solution comprises a combination of polyacrylate and chitosan.
28. The dressing of claim 22 , wherein the gel or gel-forming solution is thermoreversible.
29. The dressing of claim 22 , further comprising a non-gas forming porogen.
30. The dressing of claim 29 , wherein the non-gas forming porogen is a salt.
31. The dressing of claim 30 , wherein the salt is sodium chloride or potassium chloride.
32. The dressing of claim 29 , wherein the non-gas forming porogen is a sugar.
33. The dressing of claim 22 , wherein the bioresorbable microsphere comprises polylactide (PLA), polyglycolic acid (PLG), poly(lactide-co-glycolide) (PLGA), polyethylene glycol-PLA, PLA-polycaprolactone (PCL), a polyorthoester, a polyphosphazene, or a polyphosphoester.
34. The dressing of claim 22 , further comprising a compound that adds stiffness to the dressing.
35. The dressing of claim 34 , wherein the compound is calcium sulfate hemihydrate.
36. The dressing of claim 22 , further comprising a bioactive agent.
37. The dressing of claim 36 , wherein the bioactive agent is an antibiotic.
38. The dressing of claim 36 , wherein the bioactive agent is a growth factor.
39. The dressing of claim 38 , wherein the growth factor is growth hormone (GH), a bone morphogenetic protein (BMP), transforming growth factor-α(TGF-α), a TGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GMCSF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumor necrosis factor-α(TNF-α), or nerve growth factor (NGF).
40. The dressing of claim 22 , further comprising a mammalian cell.
41. The dressing of claim 40 , wherein the mammalian cell is an embryonic stem cell, an adult stem cell, an induced pluripotent stem cell, an epithelial cell, an endothelial cell, a mesenchymal cell, a muscle cell, a fibroblast, a chondrocyte, an adipocyte, or an osteocyte.
42. The dressing of claim 40 , wherein the mammalian cell is a human cell.
43. The tissue dressing of claim 22 , wherein the pores of the scaffold are between approximately 100 micrometers and 300 micrometers in diameter.